Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM.

J Bone Miner Res. 2011 Jul;26(7):1425-36. doi: 10.1002/jbmr.345.

2.

Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS.

Endocrinology. 2008 Apr;149(4):1757-72. Epub 2007 Dec 27.

3.
4.

MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.

Addison WN, Nakano Y, Loisel T, Crine P, McKee MD.

J Bone Miner Res. 2008 Oct;23(10):1638-49. doi: 10.1359/jbmr.080601.

5.

Calcium induces pro-anabolic effects on human primary osteoblasts associated with acquisition of mature osteocyte markers.

Welldon KJ, Findlay DM, Evdokiou A, Ormsby RT, Atkins GJ.

Mol Cell Endocrinol. 2013 Aug 25;376(1-2):85-92. doi: 10.1016/j.mce.2013.06.013. Epub 2013 Jun 18.

PMID:
23791847
7.

Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE.

Bone. 2005 Jan;36(1):33-46. Epub 2004 Nov 24.

8.

SPR4-peptide alters bone metabolism of normal and HYP mice.

Zelenchuk LV, Hedge AM, Rowe PS.

Bone. 2015 Mar;72:23-33. doi: 10.1016/j.bone.2014.11.011. Epub 2014 Nov 22.

9.

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.

Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ.

PLoS One. 2011;6(10):e25900. doi: 10.1371/journal.pone.0025900. Epub 2011 Oct 4.

10.

Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation.

Prideaux M, Loveridge N, Pitsillides AA, Farquharson C.

PLoS One. 2012;7(5):e36786. doi: 10.1371/journal.pone.0036786. Epub 2012 May 7.

11.

Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage.

Addison WN, Masica DL, Gray JJ, McKee MD.

J Bone Miner Res. 2010 Apr;25(4):695-705. doi: 10.1359/jbmr.090832.

12.

Pigment epithelium derived factor suppresses expression of Sost/Sclerostin by osteocytes: implication for its role in bone matrix mineralization.

Li F, Song N, Tombran-Tink J, Niyibizi C.

J Cell Physiol. 2015 Jun;230(6):1243-9. doi: 10.1002/jcp.24859.

PMID:
25363869
13.

Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.

Zelenchuk LV, Hedge AM, Rowe PS.

Bone. 2015 Oct;79:131-42. doi: 10.1016/j.bone.2015.05.030. Epub 2015 Jun 4.

14.

Molecular regulation of matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2.

Cho YD, Yoon WJ, Woo KM, Baek JH, Lee G, Cho JY, Ryoo HM.

J Biol Chem. 2009 Sep 11;284(37):25230-40. doi: 10.1074/jbc.M109.008391. Epub 2009 Jul 18.

15.

ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.

David V, Martin A, Hedge AM, Drezner MK, Rowe PS.

Am J Physiol Renal Physiol. 2011 Mar;300(3):F783-91. doi: 10.1152/ajprenal.00304.2010. Epub 2010 Dec 22.

16.

Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.

Boukpessi T, Gaucher C, Léger T, Salmon B, Le Faouder J, Willig C, Rowe PS, Garabédian M, Meilhac O, Chaussain C.

Am J Pathol. 2010 Aug;177(2):803-12. doi: 10.2353/ajpath.2010.091231. Epub 2010 Jun 25.

17.

MEPE is a novel regulator of growth plate cartilage mineralization.

Staines KA, Mackenzie NC, Clarkin CE, Zelenchuk L, Rowe PS, MacRae VE, Farquharson C.

Bone. 2012 Sep;51(3):418-30. doi: 10.1016/j.bone.2012.06.022. Epub 2012 Jul 7.

18.

Do ASARM peptides play a role in nephrogenic systemic fibrosis?

Rowe PS, Zelenchuk LV, Laurence JS, Lee P, Brooks WM, McCarthy ET.

Am J Physiol Renal Physiol. 2015 Nov 1;309(9):F764-9. doi: 10.1152/ajprenal.00201.2015. Epub 2015 Sep 2.

19.
20.

MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia.

Salmon B, Bardet C, Khaddam M, Naji J, Coyac BR, Baroukh B, Letourneur F, Lesieur J, Decup F, Le Denmat D, Nicoletti A, Poliard A, Rowe PS, Huet E, Vital SO, Linglart A, McKee MD, Chaussain C.

PLoS One. 2013;8(2):e56749. doi: 10.1371/journal.pone.0056749. Epub 2013 Feb 22.

Supplemental Content

Support Center